201 related articles for article (PubMed ID: 37996600)
1. Efficacy of combined tumor irradiation and K
Stransky N; Ganser K; Quintanilla-Martinez L; Gonzalez-Menendez I; Naumann U; Eckert F; Koch P; Huber SM; Ruth P
Sci Rep; 2023 Nov; 13(1):20604. PubMed ID: 37996600
[TBL] [Abstract][Full Text] [Related]
2. KCa3.1 channel inhibition sensitizes malignant gliomas to temozolomide treatment.
D'Alessandro G; Grimaldi A; Chece G; Porzia A; Esposito V; Santoro A; Salvati M; Mainiero F; Ragozzino D; Di Angelantonio S; Wulff H; Catalano M; Limatola C
Oncotarget; 2016 May; 7(21):30781-96. PubMed ID: 27096953
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of vascular calcification by block of intermediate conductance calcium-activated potassium channels with TRAM-34.
Freise C; Querfeld U
Pharmacol Res; 2014 Jul; 85():6-14. PubMed ID: 24813858
[TBL] [Abstract][Full Text] [Related]
4. Ca2+-Activated IK K+ Channel Blockade Radiosensitizes Glioblastoma Cells.
Stegen B; Butz L; Klumpp L; Zips D; Dittmann K; Ruth P; Huber SM
Mol Cancer Res; 2015 Sep; 13(9):1283-95. PubMed ID: 26041939
[TBL] [Abstract][Full Text] [Related]
5. KCa3.1 inhibition switches the phenotype of glioma-infiltrating microglia/macrophages.
Grimaldi A; D'Alessandro G; Golia MT; Grössinger EM; Di Angelantonio S; Ragozzino D; Santoro A; Esposito V; Wulff H; Catalano M; Limatola C
Cell Death Dis; 2016 Apr; 7(4):e2174. PubMed ID: 27054329
[TBL] [Abstract][Full Text] [Related]
6. K⁺-channel inhibition reduces portal perfusion pressure in fibrotic rats and fibrosis associated characteristics of hepatic stellate cells.
Freise C; Heldwein S; Erben U; Hoyer J; Köhler R; Jöhrens K; Patsenker E; Ruehl M; Seehofer D; Stickel F; Somasundaram R
Liver Int; 2015 Apr; 35(4):1244-52. PubMed ID: 25212242
[TBL] [Abstract][Full Text] [Related]
7. KCa3.1 channels are involved in the infiltrative behavior of glioblastoma in vivo.
D'Alessandro G; Catalano M; Sciaccaluga M; Chece G; Cipriani R; Rosito M; Grimaldi A; Lauro C; Cantore G; Santoro A; Fioretti B; Franciolini F; Wulff H; Limatola C
Cell Death Dis; 2013 Aug; 4(8):e773. PubMed ID: 23949222
[TBL] [Abstract][Full Text] [Related]
8. The potassium channel KCa3.1 as new therapeutic target for the prevention of obliterative airway disease.
Hua X; Deuse T; Chen YJ; Wulff H; Stubbendorff M; Köhler R; Miura H; Länger F; Reichenspurner H; Robbins RC; Schrepfer S
Transplantation; 2013 Jan; 95(2):285-92. PubMed ID: 23325003
[TBL] [Abstract][Full Text] [Related]
9. Blockade of the intermediate-conductance Ca(2+)-activated K+ channel inhibits the angiogenesis induced by epidermal growth factor in the treatment of corneal alkali burn.
Yang H; Li X; Ma J; Lv X; Zhao S; Lang W; Zhang Y
Exp Eye Res; 2013 May; 110():76-87. PubMed ID: 23482085
[TBL] [Abstract][Full Text] [Related]
10. Effects of Intermediate-Conductance Ca(2+)-Activated K(+) Channels on Human Endometrial Carcinoma Cells.
Zhang Y; Feng Y; Chen L; Zhu J
Cell Biochem Biophys; 2015 Jun; 72(2):515-25. PubMed ID: 25608633
[TBL] [Abstract][Full Text] [Related]
11. KCa3.1 ion channel: A novel therapeutic target for corneal fibrosis.
Anumanthan G; Gupta S; Fink MK; Hesemann NP; Bowles DK; McDaniel LM; Muhammad M; Mohan RR
PLoS One; 2018; 13(3):e0192145. PubMed ID: 29554088
[TBL] [Abstract][Full Text] [Related]
12. Ca2+ -activated K+ channel-3.1 blocker TRAM-34 alleviates murine allergic rhinitis.
Lin H; Zheng C; Li J; Yang C; Hu L
Int Immunopharmacol; 2014 Dec; 23(2):642-8. PubMed ID: 25466273
[TBL] [Abstract][Full Text] [Related]
13. Altered K
Seo CH; Cui HS; Kim JB
Transl Res; 2021 Oct; 236():133-146. PubMed ID: 33905948
[TBL] [Abstract][Full Text] [Related]
14. The KCa3.1 blocker TRAM-34 inhibits proliferation of fibroblasts in paraquat-induced pulmonary fibrosis.
Xie H; Lu J; Zhu Y; Meng X; Wang R
Toxicol Lett; 2018 Oct; 295():408-415. PubMed ID: 30036685
[TBL] [Abstract][Full Text] [Related]
15. Targeting of microglial KCa3.1 channels by TRAM-34 exacerbates hippocampal neurodegeneration and does not affect ictogenesis and epileptogenesis in chronic temporal lobe epilepsy models.
Ongerth T; Russmann V; Fischborn S; Boes K; Siegl C; Potschka H
Eur J Pharmacol; 2014 Oct; 740():72-80. PubMed ID: 25016931
[TBL] [Abstract][Full Text] [Related]
16. Targeted inhibition of KCa3.1 attenuates TGF-β-induced reactive astrogliosis through the Smad2/3 signaling pathway.
Yu Z; Yu P; Chen H; Geller HM
J Neurochem; 2014 Jul; 130(1):41-49. PubMed ID: 24606313
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of the Ca²⁺-dependent K⁺ channel, KCNN4/KCa3.1, improves tissue protection and locomotor recovery after spinal cord injury.
Bouhy D; Ghasemlou N; Lively S; Redensek A; Rathore KI; Schlichter LC; David S
J Neurosci; 2011 Nov; 31(45):16298-308. PubMed ID: 22072681
[TBL] [Abstract][Full Text] [Related]
18. K
Bonito B; Sauter DR; Schwab A; Djamgoz MB; Novak I
Pflugers Arch; 2016 Nov; 468(11-12):1865-1875. PubMed ID: 27752766
[TBL] [Abstract][Full Text] [Related]
19. Inhibitory effects of candesartan on KCa3.1 potassium channel expression and cell culture and proliferation in peripheral blood CD4
Li H; Zhao JL; Zhang YM; Han SX
Clin Exp Hypertens; 2018; 40(4):303-311. PubMed ID: 29388859
[TBL] [Abstract][Full Text] [Related]
20. Increased Interleukin-10 Expression by the Inhibition of Ca
Ohya S; Matsui M; Kajikuri J; Endo K; Kito H
J Pharmacol Exp Ther; 2021 Apr; 377(1):75-85. PubMed ID: 33504590
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
